Abilify: General Information and Indications for Use

Abilify is a medication for people who suffer from schizophrenia. It is used both during the exacerbation period and for maintenance therapy. Abilify is also prescribed for acute manic episodes of type 1 in manic-depressive psychosis and as a supportive treatment for bipolar affective disorders. It can be used as an auxiliary treatment for depressive disorders. According to some experts, the drug can be used to treat alcoholism.




Dosage Forms

Abilify tablets are produced in the form of round- or rectangular-shaped pills and have different dosage and color:

  • Marked with A - 007 and 5, color - blue (5 mg);
  • Marked with A - 008 and 10, color - pink (10 mg);
  • Marked with A - 009 and 15, color - yellow (15 mg);
  • Marked with A - 010 and 20, color - white or pale yellow (20 mg);
  • Marked with A - 011 and 30, color - pink (30 mg).


Abilify is an antagonist of D2 subtype dopamine receptors in the mesolimbic system, while partially being an agonist of the same receptors in the mesocortical system. The drug is a strong antagonist of serotonin 5 - HT2A receptor subtype and a 5 - HT1A receptor agonist. It has the lowest affinity to adrenoreceptors (? 1), histamine (H 1) receptors and to M-cholinoreceptors among all of the atypical antipsychotics medications. Such pharmacodynamics of Abilify explains high therapeutic effect of the drug in the treatment of schizophrenia and bipolar disorders, as well as low incidence and severity of side effects. The drug is able to lower the level of prolactin, glucose and lipids in the blood. Another essential positive property of the drug is its ability to reduce the QT-interval in ECG.


The average half-life of the active substance is about 75 hours. Isostatic concentration is noted after 14 days. The pharmacokinetics of Abilify in the isostatic state are proportional to the dosage. Fluctuations in the distribution of the active substance and its metabolites per day are not noted. The drug is rapidly absorbed. Maximum drug concentration is noted after three to five hours. The total ability to digest is 87% regardless of eating. The total purification rate is 0.7 ml / min / kg.

Usage during Pregnancy

The use of Abilify during pregnancy is allowed in situations where the expected efficacy of treatment exceeds the potential threat to a fetus. Detailed studies regarding the safety of treatment with this medicine during pregnancy have not been conducted.


Contraindications include hypersensitivity to aripiprazole or any other ingredient of the drug, as well as age up to 18 and the period of breastfeeding.

Side Effects

Side effects can include negative reactions of the following systems and organs:

  • Cardiovascular system;
  • Digestive system;
  • Musculoskeletal system;
  • Nervous and respiratory systems;
  • Skin;
  • Metabolism;
  • Genitourinary system.

Rare allergic reactions include anaphylaxis, angioedema, itching, urticaria.

Dosing and Administration

The method of administration and dose of the drug in schizophrenia is initially 10 to 15 mg once a day, regardless of the food intake. The maintenance dosage is 15 mg per day. According to clinical data, an effective daily dosage of the drug is from 10 to 30 mg. In case of manic episodes, the recommended dose at the beginning of the treatment is 15 mg per day, regardless of food intake. If the dosage adjustment is necessary, the interval should be at least 24 hours.

In treatment of depressive disorders the recommended dosage of the drug is initially 5 mg per day (when used together with antidepressant medications).


Contact your healthcare provider before starting the treatment with Abilify.